Reaktionsgleichung
C([O:5][C:6](=[O:41])[CH2:7][N:8]1[C:16]2[C:11](=[CH:12][C:13]([F:17])=[CH:14][CH:15]=2)[C:10]([C:18]2[C:23]3[CH:24]=[CH:25][CH:26]=[CH:27][C:22]=3[S:21](=[O:29])(=[O:28])[N:20]([CH2:30][CH2:31][O:32][C:33]3[CH:38]=[CH:37][C:36]([Cl:39])=[CH:35][CH:34]=3)[N:19]=2)=[C:9]1[CH3:40])(C)(C)C.C(O)(C(F)(F)F)=O>>[Cl:39][C:36]1[CH:37]=[CH:38][C:33]([O:32][CH2:31][CH2:30][N:20]2[N:19]=[C:18]([C:10]3[C:11]4[C:16](=[CH:15][CH:14]=[C:13]([F:17])[CH:12]=4)[N:8]([CH2:7][C:6]([OH:41])=[O:5])[C:9]=3[CH3:40])[C:23]3[CH:24]=[CH:25][CH:26]=[CH:27][C:22]=3[S:21]2(=[O:29])=[O:28])=[CH:34][CH:35]=1Komponenten
3
Edukt 2
Produkt 1
Versuchsvorschrift
(3-{2-[2-(4-Chloro-phenoxy)-ethyl]-1,1-dioxo-1,2-dihydro-1λ6-benzo[e][1,2,3]thiadiazin-4-yl}-5-fluoro-2-methyl-indol-1-yl)-acetic acid tert-butyl ester (61 μmol) was treated with TFA (2 mL) for 2 hours, concentrated, and purified by preparative LCMS to give the title compound. 1H NMR (d6-DMSO) δ 8.11 (d, 1H), 7.92 (t, 1H), 7.83 (t, 1H), 7.46 (m, 2H), 7.24 (m, 2H), 6.95 (m, 4H), 4.52 (s, 2H), 4.39 (t, 2H), 4.27 (t, 2H), 2.20 (s, 3H) ppm. MS calculated for C26H21FClN3O5S—H: 540, observed: 540.
Aufarbeitung
- concentrationconcentrated
- custompurified by preparative LCMS
Quellen und Nachweise
- ORD-Eintrag
- ord-caaeb650061a4c5282ce731431554aed
- Quelldatensatz
- uspto-grants-2008_07
- Patentnummer
- US07405215B2
Verknüpfte Notizen
Wird geladen…